PHIO PHARMACEUTICALS

Serial Number 88170269
606

Registration Progress

Application Filed
Oct 26, 2018
Under Examination
May 21, 2019
Approved for Publication
Mar 26, 2019
Published for Opposition
Mar 26, 2019
Registered

Basic Information

Serial Number
88170269
Filing Date
October 26, 2018
Published for Opposition
March 26, 2019
Abandonment Date
June 27, 2022
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Jun 27, 2022
Classes
005

Rights Holder

PHIO PHARMACEUTICALS CORP.

03
Address
257 SIMARANO DRIVE, SUITE 101
MARLBOROUGH, MA 01752

Ownership History

RXi Pharmaceuticals Corporation

Original Applicant
03
Marlborough, MA

PHIO PHARMACEUTICALS CORP.

New Owner Before Publication #1
03
MARLBOROUGH, MA

PHIO PHARMACEUTICALS CORP.

Owner at Publication
03
MARLBOROUGH, MA

Legal Representation

Attorney
Timothy H. Hiebert
USPTO Deadlines 2 active 2 overdue
Deadline Type Event Code Deadline Date Days Until Priority Extension Available
OPPOSITION
Notice of Publication
NPUB Apr 25, 2019 2265 days overdue Medium Until May 25, 2019
ITU SOU
Notice of Allowance Mailed - SOU Required
NOAM Nov 21, 2019 2055 days overdue High Until May 21, 2020

Application History

32 events
Date Code Type Description
Jun 27, 2022 ABN6 S ABANDONMENT - NO USE STATEMENT FILED
Jun 27, 2022 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Nov 20, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 19, 2021 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 19, 2021 EX5G S SOU EXTENSION 5 GRANTED
Nov 12, 2021 EEXT I SOU TEAS EXTENSION RECEIVED
Nov 12, 2021 EXT5 S SOU EXTENSION 5 FILED
May 14, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 12, 2021 EEXT I SOU TEAS EXTENSION RECEIVED
May 12, 2021 EXT4 S SOU EXTENSION 4 FILED
May 12, 2021 EX4G S SOU EXTENSION 4 GRANTED
Nov 13, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 11, 2020 EEXT I SOU TEAS EXTENSION RECEIVED
Nov 11, 2020 EXT3 S SOU EXTENSION 3 FILED
Nov 11, 2020 EX3G S SOU EXTENSION 3 GRANTED
May 8, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 6, 2020 EEXT I SOU TEAS EXTENSION RECEIVED
May 6, 2020 EXT2 S SOU EXTENSION 2 FILED
May 6, 2020 EX2G S SOU EXTENSION 2 GRANTED
Nov 22, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 20, 2019 EEXT I SOU TEAS EXTENSION RECEIVED
Nov 20, 2019 EXT1 S SOU EXTENSION 1 FILED
Nov 20, 2019 EX1G S SOU EXTENSION 1 GRANTED
May 21, 2019 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 26, 2019 PUBO A PUBLISHED FOR OPPOSITION
Mar 26, 2019 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 6, 2019 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 11, 2019 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 4, 2019 DOCK D ASSIGNED TO EXAMINER
Nov 28, 2018 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Nov 9, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 30, 2018 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Therapeutic pharmaceuticals for use in the treatment of cancer
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"PHARMACEUTICALS"